Log in

Relevant bibliographies by topics / Hematological malignancie / Journal articles

To see the other types of publications on this topic, follow the link: Hematological malignancie.

Journal articles on the topic 'Hematological malignancie'

Author: Grafiati

Published: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Hematological malignancie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Miao, Miao, Wu Depei, Aining Sun, Ying Wang, Lingzhi Yan, and Qian Wu. "The Efficacy and Safety of Recombinant Human Thrombopoietin in Patients with Hematological Malgnancies After Allogeneic Hematopoietic Stem Cell Transplantation." Blood 118, no. 21 (2011): 4565. http://dx.doi.org/10.1182/blood.v118.21.4565.4565.

Full text

Abstract:

Abstract Abstract 4565 OBJECTIVE: To evaluate the efficacy and sefety of recombinant human thrombopoietin(rhTPO) prior to engraftment in adults with hematological malignancie who received allogeneic haematopoietil stem cell transplantation(Allo-HSCT). METHODS: This sutdy was a randomized, controlled clinical trial,38 patients were hematological malignancie, inclulding acute and chrinic myeloid leukemia, acute lymphoblastic leukemia, lymphoma.They received Allo-HSCT and were randomly divided into groups(group A 19 cases, group B 19 cases).The group A was no-rhTPO as control, the group B were re

APA, Harvard, Vancouver, ISO, and other styles

2

Dong, L., X.-Y. Zhai, Y.-L. Yang, et al. "P110 Population pharmacokinetics and dosing optimisation of imipenem in children with haematological malignancie." Archives of Disease in Childhood 104, no. 6 (2019): e63.3-e63. http://dx.doi.org/10.1136/archdischild-2019-esdppp.148.

Full text

Abstract:

BackgroundImipenem/cilastatin is widely used for the treatment of children with serious infections. Currently, there is lack of pharmacokinetic studies of imipenem in children with hematological malignancies. Given the significant impact of disease on pharmacokinetics and increased resistance, we aimed to conduct a population based pharmacokinetic study of imipenem and optimize the dosage regimens for this vulnerable population.MethodsAfter treated with IMP/CS, blood samples of children were collected and the concentration of imipenem were quantified using HPLC-UV. Then, population level pharm

APA, Harvard, Vancouver, ISO, and other styles

3

Zinzani, Pier Luigi, Enrico Derenzini, Cinzia Pellegrini, et al. "Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial." Blood 118, no. 21 (2011): 1604. http://dx.doi.org/10.1182/blood.v118.21.1604.1604.

Full text

Abstract:

Abstract Abstract 1604 We previously reported the results of a multicenter non-randomized phase II trial of fludarabine and mitoxantrone plus radioimmunotherapy (RIT) [FLUMIZ (Fludarabine, Mitoxantrone, Zevalin) trial], demonstrating that this combination was safe and very effective in untreated patients with follicular non-Hodgkin lymphoma. We are now providing long term efficacy and toxicity results of this combination strategy. Sixty-one patients with stage III and IV untreated follicular lymphoma were enrolled between June 2004 and April 2006, at 13 Italian institutions. Briefly, treatment

APA, Harvard, Vancouver, ISO, and other styles

4

Clemmensen, Signe B., Jennifer R. Harris, Jonas Mengel-From, et al. "Familial Risk and Heritability of Hematologic Malignancies in the Nordic Twin Study of Cancer." Cancers 13, no. 12 (2021): 3023. http://dx.doi.org/10.3390/cancers13123023.

Full text

Abstract:

We aimed to explore the genetic and environmental contributions to variation in the risk of hematologic malignancies and characterize familial dependence within and across hematologic malignancies. The study base included 316,397 individual twins from the Nordic Twin Study of Cancer with a median of 41 years of follow-up: 88,618 (28%) of the twins were monozygotic, and 3459 hematologic malignancies were reported. We estimated the cumulative incidence by age, familial risk, and genetic and environmental variance components of hematologic malignancies accounting for competing risk of death. The

APA, Harvard, Vancouver, ISO, and other styles

5

Asare, Mariette, Jeanne E. Hendrickson, and Christopher A. Tormey. "Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies." Blood 128, no. 22 (2016): 1463. http://dx.doi.org/10.1182/blood.v128.22.1463.1463.

Full text

Abstract:

Abstract Introduction: Patients with hematological and oncological malignancies are among the most frequent recipients of chronic red blood cell (RBC) transfusion therapy. One of the risks associated with chronic RBC exposure is the development of blood group antibodies. However, there are few extensive studies of alloimmunization rates associated with hematological or oncological malignancies in adult patients despite the frequency with which they are transfused. As such, the aims of this study were: 1) to determine the alloimmunization rate associated with malignant conditions in general, 2)

APA, Harvard, Vancouver, ISO, and other styles

6

Liao, Yongkang, Shijun Xiong, Zaid Ur Rehman, et al. "The Research Advances of Aptamers in Hematologic Malignancies." Cancers 15, no. 1 (2023): 300. http://dx.doi.org/10.3390/cancers15010300.

Full text

Abstract:

Currently, research for hematological malignancies is very intensive, with many breakthroughs. Among them, aptamer-based targeted therapies could be counted. Aptamer is a targeting tool with many unique advantages (easy synthesis, low toxicity, easy modification, low immunogenicity, nano size, long stability, etc.), therefore many experts screened corresponding aptamers in various hematological malignancies for diagnosis and treatment. In this review, we try to summarize and provide the recent progress of aptamer research in the diagnosis and treatment of hematologic malignancies. Until now, 2

APA, Harvard, Vancouver, ISO, and other styles

7

Yang, Xiao-Jing, Ya-Ming Xi, and Zi-Jian Li. "Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy." BioMed Research International 2019 (March 28, 2019): 1–7. http://dx.doi.org/10.1155/2019/4860268.

Full text

Abstract:

Hematological malignancies including leukemia and lymphoma can severely impact human health. With the current therapies combined with chemotherapy, stem cell transplantation, radiotherapy, and immunotherapy, the prognosis of hematologic malignancies improved significantly. However, most hematological malignancies are still incurable. Therefore, research for novel treatment options was continuing with the natural product as one source. Icaritin is a compound extracted from a traditional Chinese herb,Epimedium Genus, and demonstrated an antitumor effect in various neoplasms including hematologic

APA, Harvard, Vancouver, ISO, and other styles

8

Ren, Anqi, Xiqin Tong, Na Xu, Tongcun Zhang, Fuling Zhou, and Haichuan Zhu. "CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities." Vaccines 11, no. 1 (2023): 165. http://dx.doi.org/10.3390/vaccines11010165.

Full text

Abstract:

T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically aggressive hematological malignancy with high rates of disease relapse and a poor prognosis. Current guidelines do not recommend any specific treatments for these patients, and only allogeneic stem cell transplant, which is associated with potential risks and toxicities, is a curative therapy. Recent clinical trials showed that immunotherapies, including monoclonal antibodies, checkpoint inhibitors, and CAR T therapies, are successful in treating hematologic malignancies. CAR T cells, which specifically ta

APA, Harvard, Vancouver, ISO, and other styles

9

YAEGASHI, HIROSHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, et al. "Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience." Cancer Diagnosis & Prognosis 2, no. 3 (2022): 352–59. http://dx.doi.org/10.21873/cdp.10116.

Full text

Abstract:

Background/Aim: Primary mediastinal non-seminomatous germ cell tumors (PMNSGCTs) are occasionally complicated by a hematologic malignancy, as with somatic-type malignant tumors called germ cell tumors with somatic-type malignancy (GCTSTM) and are known to have a poor prognosis. Patients and Methods: Data obtained between September 1997 and February 2020 for patients with mediastinal germ cell tumor at our institution were retrospectively analyzed. Key outcome measures included survival rates and the clinical features of non-seminoma cases. Results: Of 16 patients, 9 had pure seminoma, and 7 ha

APA, Harvard, Vancouver, ISO, and other styles

10

Krishnan, Gayathri, and Anupam Pande. "985. Fusarium Infections in Patients with Hematological Malignancies." Open Forum Infectious Diseases 8, Supplement_1 (2021): S583—S584. http://dx.doi.org/10.1093/ofid/ofab466.1179.

Full text

Abstract:

Abstract Background Fusarium is a ubiquitous mold that can cause invasive and disseminated fusariosis in immunosuppressed patients, especially those with hematological malignancies. The risk factors associated with mortality of patients with Fusarium infections have not been adequately assessed in literature. In this study, we sought to explore the characteristics, clinical outcomes, and risk factors for mortality in Fusarium infections in patients with hematological malignancies. Methods This is a retrospective study of adult hematological malignancy patients admitted to surgical/medical ward

APA, Harvard, Vancouver, ISO, and other styles

11

Iftikhar, Raheel, and Uzma Zaidi. "Interim-Guidelines for COVID-19 Vaccination in Hematological Malignancies and Hematopoietic Stem Cell Transplant Recipients." National Journal of Health Sciences 6, no. 1 (2021): 38–43. http://dx.doi.org/10.21089/njhs.61.0038.

Full text

Abstract:

Abstract: Objective: Hematologic malignancies such as Acute Leukemias, Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPNs), Lymphomas and Multiple Myeloma (MM) can be treated with chemotherapy, Hematopoietic Stem Cell Transplant (HSCT) or Chimeric Antigen Receptor T-cell (CAR-T) therapies with either a curative intent or to prolong survival. The hematologic malignancy itself or the anti-cancer therapies can result in long-term immunodeficiency; COVID-19 infection in this population is associated with a significantly higher risk of hospitalization and death [1]. Given lack of a

APA, Harvard, Vancouver, ISO, and other styles

12

Andi Cahyadi, Esthy Poespitaningtyas, Diah Kusuma Arumsari, Maria Christina Shanty Larasati, Mia Ratwita Andarsini, and I Dewa Gede Ugrasena. "Region Variation of Hematological Malignancies and Solid Tumors in Children in East Java." Asian Journal of Health Research 2, no. 1 (2023): 27–33. http://dx.doi.org/10.55561/ajhr.v2i1.71.

Full text

Abstract:

Introduction: The prevalence of childhood cancer in East Java is unevenly associated with differences in exposure to carcinogens in urban-industrial areas, agricultural chemicals, industrial waste along the river, and socio-culture. However, there are no data on regional variations in childhood cancer in East Java. We describe the regional variation of hematological malignancies and solid tumors in East Java. Material and Methods: The study was conducted by cross-sectional on children with cancer aged <18 years in dr. Soetomo General Academic Hospital in 2014-2015. The data evaluated were g

APA, Harvard, Vancouver, ISO, and other styles

13

Salem, Ahmed Ebada, Harsh R. Shah, Matthew F. Covington, et al. "PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies." Cancers 14, no. 23 (2022): 5941. http://dx.doi.org/10.3390/cancers14235941.

Full text

Abstract:

PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and evaluation of suspected recurrence. The goal of this 6-part series of review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. In the first article of this series, hematologic malignancies are addressed. The classification of these malignancies will be outlined, with the disclaimer that the classification of lymphomas is constantly evolving. Critical

APA, Harvard, Vancouver, ISO, and other styles

14

Abbagoni, Sujith, Thuy Le, Locke J. Bryan, et al. "Central Line Associated Bloodstream Infection Rate Among Hematologic Malignant Patients Who Received Antimicrobial Prophylaxis in the Inpatient Setting." Blood 138, Supplement 1 (2021): 4390. http://dx.doi.org/10.1182/blood-2021-154524.

Full text

Abstract:

Abstract Introduction: Patients with hematological malignancies are at increased risk of infections which leads to increased morbidity and mortality. Particularly, they are at an increased risk of developing central line associated bloodstream infection (CLABSI) since they frequently require central venous catheters for various essential reasons including chemotherapy, blood transfusions, and parenteral nutrition. Prophylaxis with antibiotics is the key in the management for these patients but is not always effective and sometimes associated with complications. Hence, the main objective of the

APA, Harvard, Vancouver, ISO, and other styles

15

Tsering, Lama Tamang, Sindhu Barola, and Abhinav B. Chandra. "Assessing Bacterial Isolates in Bloodstream Infections and Trend of the Antimicrobial Resistance in the Hematological and Solid Malignancies." Blood 126, no. 23 (2015): 5628. http://dx.doi.org/10.1182/blood.v126.23.5628.5628.

Full text

Abstract:

Abstract Introduction: Infection is a common cause of morbidity and mortality in hemato-oncologic patients receiving chemotherapy. The empiric broad spectrum antibiotic given to patients with fever and features of sepsis has reduced infection related complications and shortened hospital stay. However, the use of empirical antibiotic prophylaxis has caused changes in the spectrum of organisms and emergence of drug resistance. We evaluated the type of bacterial isolates and the resistance patterns in cancer patients. Method: We examined data from cancer patients aged 18 years and older with posi

APA, Harvard, Vancouver, ISO, and other styles

16

Sud, Amit, Subhayan Chattopadhyay, Hauke Thomsen, et al. "Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk." Blood 134, no. 12 (2019): 960–69. http://dx.doi.org/10.1182/blood.2019001362.

Full text

Abstract:

Abstract Sud and colleagues interrogated the familial risk of hematological malignancy in association with over 150 000 patients. The majority of hematological malignancies showed increased familial relative risk, most prominently in association with B-cell malignancies.

APA, Harvard, Vancouver, ISO, and other styles

17

Banerjee, Suvankar, Sk Abdul Amin, and Tarun Jha. "Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors." Current Chemical Biology 15, no. 1 (2021): 19–49. http://dx.doi.org/10.2174/2212796815666210203104446.

Full text

Abstract:

Background: The term “hematological malignancy” means a cluster of cancer and tumor conditions, including leukemia, lymphoma, myeloproliferative neoplasm, lymphoproliferative disorders, etc., involved with circulatory organs like blood, bone marrow, lymph, and lymph nodes. Introduction: The increase in the number of hematological malignancy-related cases in our modern society urges suitable treatment of such disease. In this current era, there is still a major deficiency in the number of suitable chemotherapeutic agents for the treatment of hematological malignancies. Methods: The researchers

APA, Harvard, Vancouver, ISO, and other styles

18

Ghimire, Krishna B., and Binay K. Shah. "Second Primary Malignancy in Diffuse Large B Cell Lymphoma (DLBCL)." Blood 124, no. 21 (2014): 2606. http://dx.doi.org/10.1182/blood.v124.21.2606.2606.

Full text

Abstract:

Introduction: Patients with non-Hodgkin lymphoma are at significantly increased risk of second primary malignancies (SPM). There are few studies on SPM in diffuse large B-cell lymphoma. We aim to evaluate the risk of SPM after diagnosis of primary DLBCL using Surveillance, Epidemiology and End Results (SEER) database. Methods: We used SEER 13 database to select adult patients with primary DLBCL diagnosed between 1992- 2009. We used SEER*Stat’s Multiple Primary - Standardized Incidence Ratios (MP-SIR) to calculate SPM in DLBCL. We analyzed SPM by age (≥20, 20-59 and ≥60 years), sex and latency.

APA, Harvard, Vancouver, ISO, and other styles

19

Dar, Lior, Niv Ben-Shabat, Shmuel Tiosano, et al. "The Incidence and Predictors of Solid- and Hematological Malignancies in Patients with Giant Cell Arteritis: A Large Real-World Database Study." International Journal of Environmental Research and Public Health 18, no. 14 (2021): 7595. http://dx.doi.org/10.3390/ijerph18147595.

Full text

Abstract:

Background: The association between giant cell arteritis (GCA) and malignancies had been widely investigated with studies reporting conflicting results. Therefore, in this study, we aimed to investigate this association using a large nationwide electronic database. Methods: This study was designed as a retrospective cohort study including GCA patients first diagnosed between 2002–2017 and age, sex and enrollment time-matched controls. Follow-up began at the date of first GCA-diagnosis and continued until first diagnosis of malignancy, death or end of study follow-up. Results: The study enrolle

APA, Harvard, Vancouver, ISO, and other styles

20

Orhan, Bedrettin, Fahir Özkalemkaş, Vildan Özkocaman, et al. "THE ROLE OF WHITE BLOOD CELL COUNT IN PERIANAL PATHOLOGIES: A RETROSPECTIVE ANALYSIS OF HEMATOLOGIC MALIGNANCIES." Mediterranean Journal of Hematology and Infectious Diseases 14, no. 1 (2022): e2022051. http://dx.doi.org/10.4084/mjhid.2022.051.

Full text

Abstract:

Background and Objective: Perianal pathologies are the most common cause of perianal infections in patients with hematological malignancies. Perianal infection diagnosis in this group of patients is difficult, thus careful anorectal examination is necessary, with imaging modalities. The literature revealed a knowledge gap on the approach of anal pathologies in patients with neutropenia during diagnosis or chemotherapy. This study aimed to examine our institutional data of perianal complications and investigate the relationship among the white blood cell-neutrophil count, perianal lesion, and t

APA, Harvard, Vancouver, ISO, and other styles

21

Shrestha, Amar Narayan, Sunil Kumar Singh, Rajiv Kumar Deo, et al. "Pattern of hematological malignancy in a tertiary level hospital in Kathmandu." Journal of Pathology of Nepal 9, no. 1 (2019): 1457–59. http://dx.doi.org/10.3126/jpn.v9i1.23355.

Full text

Abstract:

Background: Hematological malignancies involve the blood elements, marrow, lymph and lymphatic elements and are among the common malignancies afflicting the human race. They tend to involve the extremes of the ages- the young and the elderly. Materials and Methods: A hospital register based retrospective study was conducted including the data of five years duration. The confirmation of diagnosis was done with blood smear examination, bone marrow examination and flow-cytometry. The epidemiological parameters were then calculated using Microsoft Excel and SPSS. Results: Among the tot

APA, Harvard, Vancouver, ISO, and other styles

22

Hanif, Umair, Mughees Ahmed, and Imran Hanif. "HEMATOLOGICAL MALIGNANCIES." Professional Medical Journal 22, no. 03 (2015): 349–52. http://dx.doi.org/10.29309/tpmj/2015.22.03.1354.

Full text

Abstract:

Infection rate of CMV in adults is approximately 60% in the developed countriesand almost 100% in the developing countries. Objectives: To evaluate the frequency ofcytomegalovirus (CMV) infection in patients with different hematological malignancies. Design:Observational study. Setting: Gulab Devi Chest Hospital & INMOL Hospital Lahore. Period: Sixmonths. Materials and methods: The blood samples were drawn from the selected patientsafter taking their written informed consent. The DNA was extracted from the whole blood andthe polymerase chain reaction was performed for CMV DNA using CMV PCR

APA, Harvard, Vancouver, ISO, and other styles

23

Brenner, Malcolm K. "Hematological malignancies." FASEB Journal 11, no. 8 (1997): 640–48. http://dx.doi.org/10.1096/fasebj.11.8.9240966.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Giagounidis, A. A. N., U. Germing, J. S. Wainscoat, J. Boultwood, and C. Aul. "Hematological Malignancies." Hematology 9, no. 4 (2004): 271–77. http://dx.doi.org/10.1080/10245330410001723824.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bueso-Ramos, Carlos E., Alessandra Ferrajoli, L. Jeffrey Medeiros, Michael J. Keating, and Zeev Estrov. "Hematological Malignancies." Hematology 9, no. 4 (2004): 279–86. http://dx.doi.org/10.1080/10245330410001727046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Prajapati, Zankhana, Mayur Kokani, and R. Gonsai. "Clinicoepidemiological profile of hematological malignancies in pediatric age group in Ahmedabad." Asian Journal of Oncology 03, no. 01 (2017): 054–58. http://dx.doi.org/10.4103/2454-6798.209330.

Full text

Abstract:

Abstract Background: This hematological malignancy comprises a major health problem in the society due to its high mortality and morbidity. There is a need for the accurate estimation of incidence and prevalence of acute lymphocytic leukemia (ALL), and other hematological malignancies in India to estimate the true disease burden and its impact on the population which may help in formulating the guideline which helps in better risk stratification and treatment. Unfortunately, there is a real paucity if epidemiologic data on pediatric cancers in India and particularly in several parts of Gujarat

APA, Harvard, Vancouver, ISO, and other styles

27

Cole, Craig E., Alyson R. Haugen, Michelle A. Mathiason, and Vicki L. McHugh. "Screening for Psychosocial Distress in Patients with Hematological Malignancies and Identifying Specific Factors That Cause Distress throughout Stage of Disease." Blood 118, no. 21 (2011): 2086. http://dx.doi.org/10.1182/blood.v118.21.2086.2086.

Full text

Abstract:

Abstract Abstract 2086 Background: Studies incorporating measurement tools for emotional distress into clinical care for hematology patients are rare. We previously reported that distress levels of >5 on the National Comprehensive Cancer Network (NCCN) distress thermometer (DT) were significantly more likely to occur in patients who were seen within the first 30 day of presentation, women, younger patients, those with previous depression/anxiety, and those who are unmarried. However, the diagnosis of malignant or non-malignant hematologic disorder was not associated with DT levels >5. Si

APA, Harvard, Vancouver, ISO, and other styles

28

Folci, Marco, Giacomo Ramponi, Dana Shiffer, Aurora Zumbo, Michele Agosti, and Enrico Brunetta. "ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives." Journal of Immunology Research 2019 (May 6, 2019): 1–9. http://dx.doi.org/10.1155/2019/1732175.

Full text

Abstract:

The purpose of this paper is to collect and summarize all evidences relating to an association between ANCA-associated vasculitides (AAVs) and hematologic malignancies, in the form of either a paraneoplastic vasculitis or leukemias and lymphomas developing on a preexisting vasculitis. Additionally, the role of cyclophosphamide in vasculitis treatment has been assessed and compared to rituximab. Paraneoplastic AAV seems to be an uncommon presentation of hemopathies. Hematologic malignancy risk in AAV is more likely to be increased by cyclophosphamide, although not yet definitely proven. Further

APA, Harvard, Vancouver, ISO, and other styles

29

Bennett, Dimitri, Nittaya Suppapanya, and Kelly Grotzinger. "Thrombocytopenia in hematologic malignancy and solid tumors in the United States." Journal of Clinical Oncology 30, no. 15_suppl (2012): e12001-e12001. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e12001.

Full text

Abstract:

e12001 Background: Thrombocytopenia (TCP) frequently occurs in patients with hematologic or solid malignancies resulting from the underlying disease processes or a complication of cancer treatments. Severe TCP may both increase the risk of bleeding, interrupt or reduce optimal dosing with therapies. Epidemiological data on these patients are limited. Therefore, to increase our knowledge, we identified patients with hematologic & solid malignancies & assessed the frequency of primary, secondary & TCP not otherwise classified, following diagnosis & through treatment using a large

APA, Harvard, Vancouver, ISO, and other styles

30

Azhar, Hajra, Hafiz Muhammad Matloob, Nida Khalid, Ayesha Rahman, Javeria Afzal, and Najma Qureshi. "Clinico-Hematological Pattern of Haematological Malignancies in Patients Referred for Bone Marrow Examination." Pakistan Journal of Medical and Health Sciences 17, no. 1 (2023): 168–70. http://dx.doi.org/10.53350/pjmhs2023171168.

Full text

Abstract:

Background: Chromosomal translocation is a common cause among hematological malignancies thus. a different diagnostic and treatment approach is required in these cases. Aim: To determine frequencies and clinic-hematological features of different hematological malignancies among patients. Methodology: It was a descriptive cross sectional study. Patients (n=284) with hematological malignancy were enrolled from total 1080 bone marrow biopsies. Detailed history, clinical examination and hematological parameters were recorded at time of presentation. Bone marrow aspiration and trephine biopsy were

APA, Harvard, Vancouver, ISO, and other styles

31

Lim, Tristan L., David B. Lieberman, Adam R. Davis, et al. "Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms." Blood 136, Supplement 1 (2020): 2–4. http://dx.doi.org/10.1182/blood-2020-134160.

Full text

Abstract:

Germline mutations in the shelterin component protection of telomeres 1 (POT1) were recently found to be associated with familial chronic lymphocytic leukemia (CLL), melanoma, glioma, and several other familial cancer syndromes. The role of POT1 mutations in myeloid neoplasms and other hematologic malignancies, however, remains unknown. To explore the role of POT1 variants in hematologic neoplasms, we analyzed POT1 variants in 3323 consecutive patients who underwent next-generation sequencing (NGS) of a panel of hematologic malignancy-associated genes at our institution and characterized the c

APA, Harvard, Vancouver, ISO, and other styles

32

Prusila, Roosa Enni Inkeri, Marc Sorigue, Aleksi Postila, et al. "Risk of Secondary Hematological Malignancies in Patients with Follicular Lymphoma: A Retrospective Analysis of 1045 Patients Treated in the Rituximab Era." Blood 132, Supplement 1 (2018): 5330. http://dx.doi.org/10.1182/blood-2018-99-110129.

Full text

Abstract:

Abstract Introduction Follicular lymphoma (FL) is the most common indolent lymphoma. Majority of the patients with FL have a good respond to first-line treatment. Relapses are common and many patients need to be re-treated (Izutsu K. J Clin Exp Hematop 2014). Treatment results of indolent non-Hodgkin lymphomas have improved vastly in last decades. This is resulting from the use of therapeutic antibodies such as rituximab (Friedberg JW. Haematologica 2008). With improved survival the risk of secondary malignancies may be higher. Some of the regimens used in the treatment of FL, especially alkyl

APA, Harvard, Vancouver, ISO, and other styles

33

Ceken, Sabahat, Habip Gedik, Gulsen Iskender, et al. "Evaluation of Risk Factors for Mortality in Febrile Neutropenia." Journal of Infection in Developing Countries 14, no. 08 (2020): 886–92. http://dx.doi.org/10.3855/jidc.12520.

Full text

Abstract:

Introduction: We aimed to evaluate the epidemiology of infections and factors associated with mortality in patients with febrile neutropenia (FEN). Methodology: The adult patients, who developed FEN after chemotherapy due to a hematologic malignancy or a solid tumor in a training and research hospital were evaluated, retrospectively. The demographic data of the patients, underlying malignancy, administered antimicrobial therapy, microbiological findings, and other risk factors associated with mortality were evaluated. Results: A total of 135 FEN episodes of 115 patients, who compri

APA, Harvard, Vancouver, ISO, and other styles

34

Buppanharun, Jirawat, and Jakapat Vanichanan. "1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country." Open Forum Infectious Diseases 6, Supplement_2 (2019): S500—S501. http://dx.doi.org/10.1093/ofid/ofz360.1242.

Full text

Abstract:

Abstract Background Tuberculosis (TB) is an infection caused by reactivation of Mycobacterium tuberculosis. Decreasing host immune system plays an important role in pathophysiology especially in patients with human immunodeficiency virus (HIV) infection and transplant recipients. Exposure to immunosuppressive agents among patients with solid and hematologic malignancy is likely to increase risk of TB. However, characteristics of TB in this population remain scarce. Methods A single-center, retrospective descriptive study was conducted at King Chulalongkorn Memorial Hospital. Adult patients who

APA, Harvard, Vancouver, ISO, and other styles

35

Saleh, Khalid S., Jabbar S. Hassan, Ali Zaidan, and Rija A. Abdul- Ridha. "The Impact of Vaccination on Severity of COVID-19 Illness in Hematologic Malignancies Patients." Bionatura 7, no. 2 (2022): 1–6. http://dx.doi.org/10.21931/rb/2022.07.02.51.

Full text

Abstract:

Covid 19 in hematological cancer patients can lead to a deterioration in the clinical course and a reduction in life expectancy leading high fatality rate. Vaccines developed against the causative virus may reduce the severity of the disease and a decline in mortality rate. This study aims to determine the impact of vaccination on the severity of COVID-19 illness in patients with hematologic malignancies. A multicenter retrospective observational study was conducted on 60 hospitalized patients admitted to intensive care units (ICUs). All patients were previously diagnosed with leukemia or lymp

APA, Harvard, Vancouver, ISO, and other styles

36

Pak, Daniel M., and Maria S. Tretiakova. "An Unusual Manifestation of Blastic Plasmacytoid Dendritic Cell Neoplasm as a Testicular Tumor." Case Reports in Pathology 2019 (October 7, 2019): 1–4. http://dx.doi.org/10.1155/2019/9196167.

Full text

Abstract:

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy arising from precursors of plasmacytoid dendritic cells that represent less than 1% of hematological malignancies. BPDCN initially presents with cutaneous involvement and a characteristic immunophenotype of CD4, CD56, and CD123 co-expression. Upon disease progression, BPDCN shows a strong predilection for bone marrow, peripheral blood, and lymph nodes, whereas manifestations in visceral organs are rare. Significant heterogeneity in clinical presentation and immunophenotypic profile makes BPDC

APA, Harvard, Vancouver, ISO, and other styles

37

Singhrao, Ruby, Lisha Capucion, Shikha Chugh, et al. "Abstract 5236: Clinical evaluation of somatic genomic alteration annotation for hematological malignancies using tertiary analysis software." Cancer Research 82, no. 12_Supplement (2022): 5236. http://dx.doi.org/10.1158/1538-7445.am2022-5236.

Full text

Abstract:

Abstract Introduction: Next Generation Sequencing (NGS) is transitioning from research to routine in clinical practice for hematological malignancies. Data analysis and annotation of variants are significant barriers to NGS adoption. NAVIFY® Mutation Profiler (NMP) is a CE-marked*, cloud-based tertiary analysis software that provides curation, annotation, and reporting of somatic genomic alterations and biomarker signatures identified by NGS. It provides information on genomic variants based on published biomedical literature, public genomic databases, medical guidelines, drug labels, and resu

APA, Harvard, Vancouver, ISO, and other styles

38

Oktariana, Desi, Legiran Legiran, Phey Liana, et al. "Transplantasi Stem Cell untuk Keganasan Hematologi." eJournal Kedokteran Indonesia 10, no. 2 (2022): 186–93. http://dx.doi.org/10.23886/ejki.10.123.186-93.

Full text

Abstract:

Insiden keganasan hematologi terus bertambah serta memiliki tingkat morbiditas dan mortalitas yang tinggi. Keganasan hematologi adalah kondisi sel-sel hematologi seperti eritrosit, leukosit, dan trombosit, tumbuh tidak terkendali dan tidak mengalami kematian sehingga mendominasi populasinya dan tidak dapat berfungsi normal. Terapi stem cell pada keganasan hematologi yang disebut juga terapi transplantasi sumsum tulang, merupakan modalitas terapi utama untuk gangguan hematologi dan keganasan yang memungkinkan pemulihan komponen seluler darah, termasuk monosit, limfosit, basofil, eosinofil, neut

APA, Harvard, Vancouver, ISO, and other styles

39

Cooper, Kathrine A., Jonathan Lattell, Beverly Gonzalez, Stephanie Kliethermes, and Sucha Nand. "Prevalence of Multiple Primary Hematologic Malignancies Seen at a Tertiary Care Center." Blood 126, no. 23 (2015): 5017. http://dx.doi.org/10.1182/blood.v126.23.5017.5017.

Full text

Abstract:

Abstract Background: There is a paucity of data regarding patients who develop multiple unrelated hematologic malignancies. This study aims to determine the prevalence of two or more hematologic malignancies in the same patient at Loyola University Medical Center (LUMC) over a period of 7 years and to explore associations with certain clinical risk factors. Methods: After obtaining IRB approval, the electronic medical record was queried for various hematologic malignancies according to ICD-9 codes from 2007-2014. Chemotherapy-associated and transformed malignancies were excluded. In addition,

APA, Harvard, Vancouver, ISO, and other styles

40

Durand-Onaylı, Valerie, Theresa Haslauer, Andrea Härzschel, and Tanja Hartmann. "Rac GTPases in Hematological Malignancies." International Journal of Molecular Sciences 19, no. 12 (2018): 4041. http://dx.doi.org/10.3390/ijms19124041.

Full text

Abstract:

Emerging evidence suggests that crosstalk between hematologic tumor cells and the tumor microenvironment contributes to leukemia and lymphoma cell migration, survival, and proliferation. The supportive tumor cell-microenvironment interactions and the resulting cellular processes require adaptations and modulations of the cytoskeleton. The Rac subfamily of the Rho family GTPases includes key regulators of the cytoskeleton, with essential functions in both normal and transformed leukocytes. Rac proteins function downstream of receptor tyrosine kinases, chemokine receptors, and integrins, orchest

APA, Harvard, Vancouver, ISO, and other styles

41

Knight, Ann, Karin Hjorton, Christer Sundström, et al. "Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome." Journal of Rheumatology 42, no. 4 (2015): 690–94. http://dx.doi.org/10.3899/jrheum.141104.

Full text

Abstract:

Objective.Previous studies have shown that patients with granulomatosis with polyangiitis (GPA) have an increased risk of hematological malignancies, especially leukemia. Our aim was to assess clinical characteristics and treatment of patients with GPA complicated by hematological malignancies with focus on leukemia and to describe these malignancies in more detail.Methods.From the Swedish population-based patient register, all individuals with a diagnosis of GPA from 1964–2012 were identified (n = 3224). Through linkage with the Swedish Cancer Register, we searched for all cases of leukemia [

APA, Harvard, Vancouver, ISO, and other styles

42

UYSAL, Elmas, Fatih SEĞMEN, Gamze KILIÇARSLAN, and Deniz ERDEM. "The effect of malignancy on prognosis in ICU patients with COVID-19." Anatolian Current Medical Journal 4, no. 3 (2022): 284–89. http://dx.doi.org/10.38053/acmj.1117598.

Full text

Abstract:

Background: It is known that COVID-19 has a worse and poorer progression, which often might lead to death in those with comorbidities. Multiple studies have recently examined the clinical course of cancer patients with COVID-19 and new guidelines have been developed to manage this group of patients. This study aimed to evaluate the clinical course and mortality rate of cancer patients admitted to the intensive care unit (ICU) for COVID-19. Material and Method: The demographic characteristics, detailed medical history and laboratory findings of 140 patients with malignancy, who were treat

APA, Harvard, Vancouver, ISO, and other styles

43

Dimopoulos, M. A., E. Kastritis, and A. Anagnostopoulos. "Hematological malignancies: myeloma." Annals of Oncology 17 (September 2006): x136—x143. http://dx.doi.org/10.1093/annonc/mdl251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Dufva, Olli, Petri Pölönen, Oscar Brück, et al. "Immunogenomic Landscape of Hematological Malignancies." Blood 132, Supplement 1 (2018): 2596. http://dx.doi.org/10.1182/blood-2018-99-118335.

Full text

Abstract:

Abstract Understanding factors that shape the immune landscape across hematological malignancies is essential for immunotherapy development. How cancer-cell intrinsic genomic and epigenetic alterations influence immune signatures in hematological malignancies is not known. Here, we integrated over 8,000 transcriptomes of hematologic cancers and multilevel genomic datasets to investigate associations of immune states to cancer molecular subtypes, genetic and epigenetic alterations, and clinical outcomes. We utilized a resource of over 8,000 transcriptomes collected across 36 hematologic maligna

APA, Harvard, Vancouver, ISO, and other styles

45

Jacobs, Chaja F., Eric Eldering, and Arnon P. Kater. "Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19." Blood Advances 5, no. 3 (2021): 913–25. http://dx.doi.org/10.1182/bloodadvances.2020003768.

Full text

Abstract:

Abstract Tyrosine kinase inhibitors (TKIs) are used to target dysregulated signaling pathways in virtually all hematologic malignancies. Many of the targeted signaling pathways are also essential in nonmalignant immune cells. The current coronavirus severe acute respiratory syndrome coronavirus 2 pandemic catalyzed clinical exploration of TKIs in the treatment of the various stages of COVID-19, which are characterized by distinct immune-related complications. Most of the reported effects of TKIs on immune regulation have been explored in vitro, with different class-specific drugs having nonove

APA, Harvard, Vancouver, ISO, and other styles

46

Bachir Bouiadjra, Chahrazed, Oum Kaltoum Seddiki, and Mustapha Bachir Diaf. "Hematologic malignancies in children: Epidemiological aspects in the pediatric oncology department of Oran Anti-Cancerous center, Algeria (2009-2013)." Journal of Drug Delivery and Therapeutics 10, no. 4 (2020): 168–74. http://dx.doi.org/10.22270/jddt.v10i4.4248.

Full text

Abstract:

The incidence of the hematological malignacies, cancers of blood and lymphoid organs, has been in continuous increase for the last 20 years. In Algeria, few data on hematologic malignancies are available in the absence of a population register. The aim of this work is to describe the epidemiological aspect of hematologic malignancies in children from northwestern Algeria. This study was carried out in 366 patients, with hematological malignancies, aged from 1 month to 15 years, over a period of 5 years (2009-2013). The study was carried out in the Anti-Cancerous Centre of Oran, Algeria.&

APA, Harvard, Vancouver, ISO, and other styles

47

Hagiwara, Shotaro, Yoshinari Suzuki, Akihiro Nakayama, Akihiro Matsunaga, Yutaka Iida, and Mari Shimura. "Multiple Elements Classified Hematological Malignancies from Healthy Population." Blood 124, no. 21 (2014): 5959. http://dx.doi.org/10.1182/blood.v124.21.5959.5959.

Full text

Abstract:

Abstract Introduction It is a little known about how multiple elements interacts and functions in cells, although a specific element had already reported to take a role, enzymatic, transcriptional activities, etc. Although, several metals such as cadmium, nickel, lead, and chrome were known as carcinogen, it is also not known about relations of multiple elements in disease mechanisms. To investigate the impact of multiple elements on the features of hematological malignancies, we analyzed the multiple elements in the serum of patients with hematological malignancies and healthy persons. Method

APA, Harvard, Vancouver, ISO, and other styles

48

Meng, Yee Choon, Mervyn Yong Hwang Koh, Zi Yan Chiam, Jun Jun Zhang, and Yin Mei, Allyn Hum. "A retrospective review of patients with hematological malignancy referred to an inpatient palliative care service in a tertiary hospital." Journal of Clinical Oncology 35, no. 31_suppl (2017): 117. http://dx.doi.org/10.1200/jco.2017.35.31_suppl.117.

Full text

Abstract:

117 Background: Patients with hematological malignancies are referred to palliative care service later and less often than patients with solid organ tumor. However, there are no data in Singapore, on the referral pattern among patients with hematological malignancy. The objective of the study is to identify the characteristics and outcomes of patients with hematological malignancy referred to an In-patient Palliative Care Service (PCS). Methods: We performed a retrospective review of all patients with hematological malignancies referred to the in-patient PCS from December 2015 to December 2016

APA, Harvard, Vancouver, ISO, and other styles

49

Guilbert, Marie-Christine, Jason L. Hornick, Sona A. Chikarmane, and Susan C. Lester. "Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression." Breast Cancer: Basic and Clinical Research 13 (January 2019): 117822341983098. http://dx.doi.org/10.1177/1178223419830982.

Full text

Abstract:

Background: Distinguishing breast hematologic malignancies in core needle biopsies from other entities can be challenging. Misclassification as a breast carcinoma could result in inappropriate treatment. The aim of this study was to characterize the types, incidence, and helpful diagnostic features of hematologic malignancies of the breast. Design: All hematologic malignancies of the breast diagnosed at our institution from 2004 to 2017 were identified. Clinical notes, imaging, and slides were reviewed. Immunohistochemical analysis of estrogen receptor α (ERα), estrogen receptor β (ERβ), and a

APA, Harvard, Vancouver, ISO, and other styles

50

Wagner, Timothy, Qais Naziri, W. North, et al. "Hematologic Malignancies Are Associated with Adverse Perioperative Outcomes following Total Knee Arthroplasty." Journal of Knee Surgery 31, no. 04 (2017): 291–301. http://dx.doi.org/10.1055/s-0037-1603335.

Full text

Abstract:

AbstractThe treatment of hematologic malignancies has advanced over the years, resulting in an improved survival of patients. As a result, these patients may be a part of the increasing population requiring total knee arthroplasty (TKA); however, they might be at a higher risk of adverse perioperative outcomes. The purpose of this study was to determine the perioperative outcomes (complications, length of stay [LOS], and costs) of patients with hematologic malignancies following TKA. This study used the Nationwide Inpatient Sample (NIS) to identify patients who underwent TKA in the United Stat

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!